Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patien
Go back to Neurocrine Biosciences Presents New Clinically Meaningful Response Data on Treatment of Tardive Dyskinesia, Reinforcing the Efficacy of INGREZZA® (valbenazine) Capsules Across a Broad Range of Patien| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 161.44 -0.18 (0.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $161.62 | 52 Week High | $58.46 | |||
| Open | $161.62 | 52 Week Low | $31.25 | |||
| Day High | $163.53 | P/E | N/A | |||
| Day Low | $160.42 | EPS | $-0.69 | |||
| Volume | 1,076,139 | |||||
